ISHIKAWA, T., ABE, S., KOJIMA, Y., HORIGOME, R., SANO, T., IWANAGA, A., . . . YOSHIDA, T. (2015). Telaprevir-based triple therapy following partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve. Exp Ther Med.
Citação norma ChicagoISHIKAWA, TORU, SATOSHI ABE, YUICHI KOJIMA, RYOKO HORIGOME, TOMOE SANO, AKITO IWANAGA, KEIICHI SEKI, TERASU HONMA, and TOSHIAKI YOSHIDA. "Telaprevir-based Triple Therapy Following Partial Splenic Arterial Embolization for Chronic Hepatitis C With Thrombocytopenia Can Reduce Carcinogenesis and Improve Hepatic Function Reserve." Exp Ther Med 2015.
Citação norma MLAISHIKAWA, TORU, et al. "Telaprevir-based Triple Therapy Following Partial Splenic Arterial Embolization for Chronic Hepatitis C With Thrombocytopenia Can Reduce Carcinogenesis and Improve Hepatic Function Reserve." Exp Ther Med 2015.